Analysts/Institutional Investor Meet/Con. Call Updates

Date: 3rd August 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Transcript of Con Call. Transcript of the discussion on the Un-audited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026, at the analyst meet held on July 29, 2026, is attached and also available on the website of the Company at Sakar-Q1-FY27-Earnings-Conference-Call-Transcript.pdf This is for information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER Encl: As above “Sakar Healthcare Limited Q1 FY27 Earnings Conference Call” July 29, 2026 MANAGEMENT: MR. BIKRAMJIT GHOSH – VICE PRESIDENT, STRATEGY AND BUSINESS DEVELOPMENT – SAKAR HEALTHCARE LIMITED MR. DHARMESH THAKER – CHIEF FINANCIAL OFFICER – SAKAR HEALTHCARE LIMITED MR. BHARAT SONI – COMPANY SECRETARY – SAKAR HEALTHCARE LIMITED MS. PUSHPA PONMANY – MANAGER – SAKAR HEALTHCARE LIMITED MODERATOR: MS. SEJAL – MUFG INTIME Page 1 of 16 Sakar Healthcare Limited July 29, 2026 Moderator: Ladies and gentlemen, good day and welcome to Sakar Healthcare Limited Q1 FY27 Earnings Conference Call, hosted by MUFG Intime. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Sejal from MUFG Intime. Thank you and over to you, ma'am. Sejal: Thank you, Shruthi. Welcome to Sakar Healthcare Q1 FY27 Earnings Con Call. Today on the call, we have Mr. Bikramjit Ghosh, Vice President Strategy and Business Development; Mr. Dharmesh Thaker, CFO; Mr. Bharat Soni, Company Secretary; and Ms. Pushpa Ponmany, Manager. Before we proceed with the call, I would like to give a small disclaimer that the call may contain certain forward-looking statements which are based on the business opinions and expectations of the company as on date. A detailed disclaimer has been given in the company's investor presentation which is uploaded on the stock exchange. Now, I would like to hand over the call to Ms. Pushpa. Over to you, ma'am. Pushpa Ponmany: Good afternoon, everyone. I welcome all our shareholders, investors, and analysts and stakeholders to the Earnings Call of Sakar Healthcare Limited for the quarter ended 30th June 2026. The first quarter of FY27 has been encouraging for Sakar Healthcare, both operationally and financially. Over the last few years, we have built an oncology business with a clear objective to establish a strong presence in global markets through differentiated products, regulatory-driven market access, and long-term commercial partnerships. As we move forward, we see Sakar evolving into a predominantly oncology-led export franchise. Our efforts across product development, dossiers, marketing authorization, technology transfers, and API integration are all aligned towards building a larger and more sustainable oncology export business over the coming years. What we are witnessing today is a steady increase in opportunities across all three areas. During the quarter, we executed more than 65 oncology product contracts and advanced discussions for over 50 additional opportunities across multiple international markets. This growing activity reflects the increasing demand for oncology products and the rising acceptance of Sakar among global pharmaceutical companies. A major focus area for us continues to be market access. The strength of any global oncology business is determined not only by the products it develops, but by the markets it can access and commercialize them in. During the quarter, we shared 261 oncology dossiers globally, with 178 already submitted and 16 marketing authorizations received. Page 2 of 16 Sakar Healthcare Limited July 29, 2026 We also completed 26 European filings, including 15 own filings. What is particularly important is that every approval expands our footprint into new markets and creates additional opportunities for future product launches. Today, our regulatory pipeline is wider than it has been ever, providing us with increased visibility across regulated as well as emerging markets. At the same time, our product portfolio continues to deepen. We have now developed 55 oncology molecules with 32 dossiers ready for launch globally. This allows us to continuously engage with partners across different regions while broadening our commercialization opportunities. Another area where we are seeing meaningful progress is customer engagement. Technology transfer projects have become an increasingly important part of our oncology business model. We currently have 33 ongoing oncology technology transfer projects with leading pharmaceutical companies, including Accord-Intas, Torrent, Emcure, Glenmark, and Zydus. Seven projects have already secured site variation approvals across the UK and European Union. These projects are important because they create long-term relationships and establish Sakar as a strategic manufacturing partner rather than simply a product supplier. Our collaboration with Zydus Lifesciences during the quarter further reinforces this trend and marks our 40th global anti-cancer product agreement. We also continue to strengthen the economics of our business through backward integration. With 21 oncology APIs developed in-house, including 16 APIs supported by written confirmations along with CEP approvals and ongoing CEP applications, we are steadily improving control over our supply chain while enhancing our competitiveness in international markets. All of this is supported by our integrated EU-GMP approved oncology facility at Bavla, which remains our cornerstone of our export strategy and enables us to address opportunities across oral solids, injectables, oral liquid, and API from a single manufacturing platform. What gives us confidence about the future is not only the strength of our pipeline but also the scalability of the platform we have created. The Bavla oncology facility has been designed with significant growth potential and we believe it can support revenues of INR800 crores to INR1,000 crores at optimal utilization over the next 4 to 5 years without requiring any major incremental capital expenditure. Given the current level of utilization, we continue to see substantial headroom for growth, operating leverage, and margin expansion as product registrations convert into commercial launches and export volumes scale up. Alongside oncology, our Changodar facility continues to support our non-oncology operations, providing stability through CDMO services, injectables, oral solids, and branded formulations. Our export portfolio today spans APAC, Latin America, CIS, Africa, and selected European markets, creating a diversified international revenue base. We are also encouraged by the recognition received from the Ethiopian Pharmaceutical Supply Services, where Sakar was recognized as one of the best suppliers for 2024-2025. Page 3 of 16 Sakar Healthcare Limited July 29, 2026 We believe such recognition reflects our growth, credibility, execution capability, and commitment to serving international healthcare markets. Coming to our financial performance, revenue from operations for quarter 1, financial year 2027 stood at INR7,297 lakhs, delivering a year-on-year growth of 38%. EBITDA increased by 67% to INR2,125 lakhs, while EBITDA margins improved to 29%. Profit after tax stood at INR1,028 lakhs, recording a growth of 120% over the corresponding quarter for the previous year. Our onco [Showing first 8,000 characters — download PDF for full document]